Hypoglycemia as a barrier to glycemic control

Journal of Diabetes and its Complications

Volumn 18, Issue 1, 2004, Pages 60-68

  Davis, Stephen ^a   Alonso, Miriam D ^b  

^a VANDERBILT UNIVERSITY HOSPITAL   (United States)

^b Ingenix   (United States)

Author keywords

Diabetes; Glucose counterregulation; Glycemia; Hypoglycemia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

CLINICAL FEATURE; DRUG ABSORPTION; DRUG EFFECT; DRUG EXCRETION; DRUG FORMULATION; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; INTENSIVE CARE; MEDICAL PRACTICE; NIGHT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCIENCE; TIME; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 1542618210     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(03)00058-8     Document Type: Article

References (64)

1. Abraira C., Colwell J., Nuttall F., Sawin C.T., Henderson W., Comstock J.P., Emanuele N.V., Levin S.R., Pacold I., Lee H.S. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VACSDM) Group Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Archives of Internal Medicine. 157:1997;181-188.
2. American College of Endocrinology/American Association of Clinical Endocrinologists (ACE/AACE) ACE consensus statement on guidelines for glycemic control. Endocrine Practice. 8(Suppl. 1):2002;5-40.
3. American Diabetes Association Standards of medical care for patients with diabetes mellitus. Diabetes Care. 26(Suppl. 1):2003;S33-S50.
4. American Diabetes Association Physical activity/exercise and diabetes mellitus. Diabetes Care. 26(Suppl. 1):2003;S73-S77.
5. American Diabetes Association Insulin administration. Diabetes Care. 26(Suppl. 1):2003;S121-S124.
6. American Diabetes Association Diabetic nephropathy. Diabetes Care. 26(Suppl. 1):2003;S94-S98.
7. Anderson J.H. Jr., Brunelle R.L., Koivisto V.A., Pfutzner A., Trautmann M.E., Vignati L., DiMarchi R. for the Multicenter Insulin Lispro Study Group Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 46:1997;265-270.
8. Austin E.J., Deary I.J. Effects of repeated hypoglycemia on cognitive function: a psychometrically validated reanalysis of the Diabetes Control and Complications Trial data. Diabetes Care. 22:1999;1273-1277.
9. Bell D.S.H., Yumuk V. Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes treated with sulfonylurea or insulin. Endocrine Practice. 3:1997;281-283.
10. Ben-Ami H., Nagachandran P., Mendelson A., Edoute Y. Drug-induced hypoglycemic coma in 102 diabetic patients. Archives of Internal Medicine. 159:1999;281-284.
11. Bischof M.G., Ludwig C., Hofer A., Kletter K., Krebs M., Stingl H., Nowotny P., Waldhausl W., Roden M. Hormonal and metabolic counterregulation during and after high-dose insulin-induced hypoglycemia in diabetes mellitus type. Hormone and Metabolic Research. 32:2000;417-423.
12. Brange J., Owens D.R., Kang S., Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 13:1990;923-954.
13. Brange J., Volund A. Insulin analogs with improved pharmacokinetic profiles. Advanced Drug Delivery Reviews. 35:1999;307-335.
14. Brouhard B.H. Long-term neurological consequences of hypoglycemia. Diabetes Care. 15:1992;583-584.
15. Burge M.R., Schade D.S. Insulins. Endocrinology and Metabolism Clinics of North America. 26:1997;575-598.
16. Burge M.R., Schmitz-Fiorentino K., Fischette C., Qualls C.R., Schade D.S. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA. 279:1998;137-143.
17. Campbell R.K. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Annals of Pharmacotherapy. 32:1998;1044-1052.
18. Carroll M.F., Izard A., Riboni K., Burge M.R., Schade D.S. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. Diabetes Care. 25:2002;2147-2152.
19. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates on diabetes. (2002). Available at: http://www.cdc.gov/ diabetes/pubs/estimates.htm. Accessed April 14, 2003.
20. Chung M., Kourides I., Canovatchel W., Sutfin T., Messig M., Chaiken R.L. Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus. Journal of Clinical Pharmacology. 42:2002;651-657.
21. Clarke W.L., Cox D.J., Gonder-Frederick L.A., Julian D., Schlundt D., Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care. 18:1995;517-522.
22. Cryer P.E. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 45:2002;937-948.
23. Davis S.N., Galassetti P., Wasserman D.H., Tate D. Effects of antecedent hypoglycemia on subsequent counterregulatory responses to exercise. Diabetes. 49:2000;73-81.
24. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine. 131:1999;281-303.
25. Diabetes Control and Complications Trial (DCCT) Research Group Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care. 11:1988;567-573.
26. Diabetes Control and Complications Trial (DCCT) Research Group Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. American Journal of Medicine. 90:1991;450-459.
27. Diabetes Control and Complications Trial (DCCT) Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 329:1993;977-986.
28. Diabetes Control and Complications Trial (DCCT) Research Group Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care. 18:1995;1415-1427.
29. Diabetes Control and Complications Trial (DCCT) Research Group Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 46:1997;271-286.
30. Edelman S.V., Henry R.R. Diagnosis and management of type 2 diabetes. 4th ed. 2001;Professional Communications, Caddo, OK.
31. Fanelli C.G., Pampanelli S., Porcellati F., Bolli G.B. Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. Diabetologia. 41:1998;720-723.
32. Frier B. Hypoglycaemia - clinical consequences and morbidity. International Journal of Clinical Practice. 2000;51-55. Suppl.
33. Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedlak M., Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 23:2000;644-649.
34. Heise T., Weyer C., Serwas A., Heinrichs S., Osinga J., Roach P., Woodworth J., Gudat U., Heinemann L. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care. 21:1998;800-803.
35. Henry R.R., Gumbiner B., Ditzler T., Wallace P., Lyon R., Glauber H.S. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care. 16:1993;21-31.
36. Hepburn D.A., Deary I.J., Frier B.M., Patrick A.W., Quinn J.D., Fisher B.M. Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach. Diabetes Care. 14:1991;949-957.
37. Hollander P.A., Schwartz S.L., Gatlin M.R., Haas S.J., Zheng H., Foley J.E., Dunning B.E. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care. 24:2001;983-988.
38. Holleman F., Hoekstra J.B.L. Insulin lispro. New England Journal of Medicine. 337:1997;176-183.
39. Holstein A., Plaschke A., Egberts E.-H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes/Metabolism Research and Reviews. 17:2001;467-473.
40. Joslin Diabetes Center & Joslin Clinic. (2002). Joslin Diabetes Center & Joslin Clinic clinical guideline for adults with diabetes. Available at: http://diabetesmanagement.joslin.org/Guidelines/Adult_ClinGuide. pdf. 2002.
41. Kerr D. Continuous blood glucose monitoring: detection and prevention of hypoglycaemia. International Journal of Clinical Practice. 2001;43-46.
42. Koivisto V.A., Yki-Järvinen H., Helve E., Karonen S.-L., Pelkonen R. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes. 35:1986;78-82.
43. Landstedt-Hallin L., Adamson U., Lins P.-E. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 84:1999;3140-3145.
44. Leporc M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., Cordoni C., Costa E., Brunetti P., Bolli G.B. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPII insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 49:2000;2142-2148.
45. MacLeod K.M. Hypoglycaemia unawareness: causes, consequences and treatment. Journal of the Royal College of Physicians of London. 34:2000;245-250.
46. Metzger M., Leibowitz G., Wainstein J., Glaser B., Raz I. Reproducibility of glucose measurements using the glucose sensor. Diabetes Care. 25:2002;1185-1191.
47. Mitrakou A., Ryan C., Veneman T., Mokan M., Jenssen T., Kiss I., Durrant J., Cryer P., Gerich J. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 260:1991;E67-E74.
48. Ovalle F., Fanelli C.G., Paramore D.S., Hershey T., Craft S., Cryer P.E. Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypolycemia in type 1 diabetes mellitus. Diabetes. 47:1998;1472-1479.
49. Pitzer K.R., Desai S., Dunn T., Edelman S., Jayalakshmi Y., Kennedy J., Tamada J.A., Potts R.O. Detection of hypoglycemia with the Gluco Watch biographer. Diabetes Care. 24:2001;881-885.
50. Porter P.A., Bryne G., Stick S., Jones T.W. Nocturnal hypoglycaemia and sleep disturbances in young teenagers with insulin dependent diabetes mellitus. Archives of Disease in Childhood. 75:1996;120-123.
51. Ratner R.E., Hirsch I.B., Neifing J.L., Garg S.K., Mecca T.E., Wilson C.A. for the U.S. Study Group of Insulin Glargine in Type 1 Diabetes Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 23:2000;639-643.
52. Reichard P., Britz A., Rosenqvist U. Intensified conventional insulin treatment and neuropsychological impairment. BMJ. 303:1991;1439-1442.
53. Rosak C., Haupt E., Walter T., Werner J. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes, Nutrition & Metabolism. 15:2002;143-151.
54. Santiago J.V., Levandoski L.A. Hypoglycemia in patients with type 1 diabetes. Lebovitz H.E. Therapy for diabetes mellitus and related disorders. 3rd ed. 1998;241-251 American Diabetes Association, Alexandria, VA.
55. Segel S.A., Paramore D.S., Cryer P.E. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 51:2002;724-733.
56. Shorr R.I., Ray W.A., Daugherty J.R., Griffin M.R. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Archives of Internal Medicine. 157:1997;1681-1686.
57. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. on behalf of the UK Prospective Diabetes Study Group Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 321:2000;405-412.
58. Torjesen P.A., Birkeland K.I., Anderssen S.A., Hjermann I., Holme I., Urdal P. Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial. Diabetes Care. 20:1997;26-31.
59. Towler D.A., Havlin C.E., Craft S., Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 42:1993;1791-1798.
60. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
61. Veneman T., Mitrakou A., Mokan M., Cryer P., Gerich J. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes. 42:1993;1233-1237.
62. Weyer C., Heise T., Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 20:1997;1612-1614.
63. White N.H., Skor D.A., Cryer P.E., Levandoski L.A., Bier D.M., Santiago J.V. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. New England Journal of Medicine. 308:1983;485-491.
64. Yki-Järvinen H., Dressler A., Ziemen M. for the HOE 901/3002 Study Group Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 23:2000;1130-1136.